NCT02790515: Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation |
|
|
| Recruiting | 2 | 52 | US | Anti-thymocyte globulin (rabbit), Thymoglobulin®, rabbit ATG, Blinatumomab, Blincyto, Cyclophosphamide, Cytoxan, Fludarabine, Fludara, G-CSF, Filgrastim, Neupogen®, Melphalan, L-phenylalanine mustard, Phenylalanine mustard, L-PAM, L-sarcolysin, Alkeran, Mesna, Mesnex, Rituximab, Rituxan™, Tacrolimus, FK506, Prograf®, Protopic®, Thiotepa, Thioplex® by Immunex, TESPA, TSPA, HPC,A Infusion, Transplant, CliniMACS, Cell Selection System, Sirolimus, Rapamycin, Rapamune® | St. Jude Children's Research Hospital | Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myeloid Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL) | 07/24 | 07/25 | | |
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 170 | US | CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine | Cyteir Therapeutics, Inc. | Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer | 07/24 | 12/24 | | |
